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Abstract 
 
The transcription factor SOX10 is essential for survival and proper differentiation 
of neural crest cell lineages, where it plays an important role in the generation 
and maintenance of melanocytes. SOX10 is also highly expressed in melanoma 
tumors, but a role in disease progression has not been established. Here we 
report that melanoma tumor cell lines require wild-type SOX10 expression for 
proliferation, and SOX10 haploinsufficiency reduces melanoma initiation in the 
metabotropic glutamate receptor 1 (Grm1Tg) transgenic mouse model. Stable 
SOX10 knockdown in human melanoma cells arrested cell growth, altered 
cellular morphology, and induced senescence. Melanoma cells with stable loss of 
SOX10 were arrested in the G1 phase of the cell cycle, with reduced expression 
in the melanocyte determining factor MITF, elevated expression of p21WAF1 and 
p27KIP2, hypophosphorylated RB and reduced levels of its binding partner E2F1.  
Since cell cycle dysregulation is a core event in neoplastic transformation, the 
role for SOX10 in maintaining cell cycle control in melanocytes suggests a 
rational new direction for targeted treatment or prevention of melanoma.  
 
Introduction 
Melanocytes are melanin-producing cells of neural crest origin located in 
the dermis and epidermis of the skin, the eye, the inner ear, and mucosal 
membranes. During development, differentiating melanocytes migrate from the 
neural tube to these distinct anatomical locations, each with unique cellular 
environments and potential for UV exposure. Malignancy of melanocytes results 
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in melanoma, an aggressive and often fatal cancer. Moreover, melanoma 
incidence is increasing worldwide; the American Cancer Society describes 
melanoma as a disease affecting a wide range of ages, and projects diagnosis of 
≈76,600 new cases in 2013 (1). Classification of melanoma subtypes 
incorporates anatomical melanocyte location, degree of sun exposure, and 
histopathology in addition to genetic categorization based upon mutations in the 
MAPK signaling pathway components BRAF, NRAS, KIT, GNA11 and GNAQ 
(2)(3)(4)(5). While recent targeted therapies to mutant BRAF hold promise, the 
majority of treated individuals with melanoma ultimately exhibit chemoresistance 
(6). Given the heterogeneity exhibited in melanoma, not only between tumor 
subtypes, but also the molecular diversity within individual lesions (7), there is a 
paramount need to identify and functionally assess additional genes fundamental 
to the regulation of melanoma growth and metastasis.   
Increasing correlations are being discovered between genes that regulate 
developmental processes and the genes and signaling pathways mediating 
tumor progression through proliferation, invasion and metastasis. Specification, 
survival and differentiation of neural crest-derived lineages including melanocytes 
is dependent on SOX10 (SRY (sex determining region Y)-box 10), a member of 
the high-mobility-group domain SOX family of transcription factors. The ≈50 
known heterozygous germline mutations in SOX10 have been linked to 
developmental neurocristopathies Waardenburg syndrome (Types II and IV) and 
PCWH (peripheral demyelinating neuropathy, central dysmyelinating 
leukodystrophy, Waardenburg syndrome and Hirschsprung disease) (8). SOX10 
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regulates many targets during neural crest development, including 
Microphthalmia-associated transcription factor (MITF), which is necessary for 
normal melanocyte development. SOX10’s regulation of MITF has implications in 
melanomagenesis, as MITF mutations and amplifications have been identified in 
a subset of melanomas (9)(10). MITF activates genes involved in melanocyte 
survival, such as BCL2 (11) and plays a key role in cell cycle via regulation of 
cyclin-dependent kinase inhibitor 2A (INK4A or CDKN2A), cyclin-dependent 
kinase inhibitor 1B (p27 or CDKN1B) and p53 (TP53) (12)(13)(14). 
In this study we evaluate the role of SOX10 in melanomagenesis. We 
examine the mutation spectrum of SOX10 in primary and metastatic melanoma 
tumor samples from multiple histological subtypes and discover a low frequency 
of mutations. We assess the effects of reduced SOX10 levels on melanoma 
growth and survival, and we demonstrate a G1 cell cycle arrest results from a 
loss of SOX10. We also confirm SOX10 expression is fundamental for 
melanomagenesis in vivo by demonstrating that a reduction in SOX10 
expression reduces tumor formation in the Grm1Tg melanoma mouse model. 
Together these results indicate reducing SOX10 levels has fateful consequences 
for melanoma formation and expansion, suggesting SOX10 is a promising target 
for melanoma treatment.   
 
Materials and Methods:  
PCR, sequencing and mutational analysis 
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Melanoma genomic DNA samples provided by Dr. Nicola Schönewolf (University 
Hospital of Zurich) and Dr. Boris Bastian (UCSF). Additional samples from Dr. 
Nicholas Hayward were sequenced at the Queensland Institute of Medical 
Research. Cell lines provided by Joanne Hasskamp (Maryland Melanoma Center 
at MedStar Franklin Square Medical Center) and the University of Arizona 
Cancer Center (UACC). Genomic DNA isolated using DNeasy Blood & Tissue 
kits (Qiagen, Valencia, CA). PCR and sequencing primers (Supplemental table 1) 
designed using NetPrimer (http://www.premierbiosoft.com/netprimer/index.html) 
and synthesized by Invitrogen (Carlsbad, CA). SOX10 coding regions amplified 
with TaKaRa LA Taq™ DNA Polymerase (Takara Bio U.S.A., Madison, WI) and 
sequencing carried out using BigDye® Terminator v3.1 (Applied Biosystems, 
Carlsbad, CA). Sequence data analyzed with Sequencher 4.9 software (Gene 
Codes Corporation, Ann Arbor, MI).  
Cell Culture, siRNA transfection and generation of stable shRNA lines 
UACC melanoma cell line isolations were described previously (15); 0002-ARM-
032702 (0002-ARM, IRB protocol number 97-79), 0391-LNA-122304 (0391-LNA, 
IRB protocol number 2003-131), and 0380-MMU-071802 (0380-MMU) cell lines 
generated from patients at the Maryland Melanoma Center following standard 
surgical consent (16). Cell lines maintained at 37°C with 5% CO2 in DMEM 
(UACC 1022, 3093) or IMDM (0380-MMU, 0391-LNA and 0002-ARM) 
supplemented with 10% FBS and 2 mM L-glutamine (Invitrogen, Carlsbad, CA). 
To generate stable shRNA cell lines, melanoma cells were infected with pLKO1 
lentiviral shRNA supernatant produced in 293T packaging cell line as described 
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previously (17). Infected cells were selected with dose of puromycin antibiotic, 
and cultured 3-6 days before knockdown screening and functional assays. For 
transient transfection of siRNA duplexes, cells treated with siRNA-Lipofectamine 
2000 reagent complexes for 72 hours prior to harvesting. RNAi 27mer duplexes 
targeting SOX10 synthesized by Integrated DNA Technologies (Coralville, IA). 
siRNA sequences used in this analysis were: SOX10si_1 - 5’ 
AGACAAAGAAUGAGGUUAUUGGCACAG 3’, SOX10si_2 - 5’ 
GGUGCAACAGUCAACCUCCUUCUCCUC 3’, and non-silencing control - 
siGENOME non-targeting siRNA pool #2 (Thermo Scientific, Waltham, MA).   
Immunoblotting 
Protein gels and Western blots were performed using standard 
protocols.  Primary antibodies were: monoclonal SOX10 (R&D Systems 
#MAB2864, Minneapolis, MN), monoclonal alpha-Tubulin (Calbiochem #CP06, 
San Diego, CA), total RB and Phospho-RB Ser807/811 antibody kit (Cell 
Signaling #9969, Danvers, MA), polyclonal E2F1 (Cell Signaling #3742), 
monoclonal p16 (F-12 Santa Cruz Biotechnology #sc-1661), monoclonal p21 
Waf1/Cip1 (Cell Signaling #2946), monoclonal cyclin D1 (BD Pharmingen 
#G124-326, Franklin Lakes, NJ), monoclonal p27 (Santa Cruz Biotechnology 
#sc-1641), polyclonal CDK2, CDK4 and CDK6 (Santa Cruz Biotechnology #sc-
163, sc-601, and sc-177, respectively) and monoclonal MITF (generously 
provided by Heinz Arnheiter). HRP-conjugated secondary antibody from Jackson 
ImmunoResearch Laboratories (West Grove, PA). 
Proliferation Assay 
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Melanoma cell lines stably expressing non-silencing or SOX10-specific shRNA 
were examined by seeding into 12-well plates (15,000 cells per well) and 
culturing 14-16 days. Cells were fed fresh growth media once a week. Samples 
analyzed every 48-72 hours by Vi-CELL counter (Beckman Coulter, Atlanta, GA). 
All samples run in duplicate, in two or three independent assays.     
Immunohistochemistry 
Cells seeded into 8-well chamber CC2 coated slides (Thermo Fisher Scientific) 
one day before staining. Cells rinsed with 1X PBS, fixed in 4% paraformaldehyde 
for 10 minutes, rinsed briefly with 1X PBS 0.1% Tween, then permeabilized with 
0.1% Triton for 10 minutes. Following 30 minute block in 1mg/mL BSA (Sigma 
#A3059), cells were incubated 2 hours with primary antibodies in block (anti-
SOX10, Santa Cruz, sc-17342; anti-HP1β, Millipore, MAB3448). Cells then 
rinsed and incubated 20 minutes in Alexa 488 or 568 secondary antibodies 
(Invitrogen) diluted in block. Cells rinsed before mounting with ProLong Gold 
mounting media with DAPI (Invitrogen). Cell images taken on Zeiss 
AxioImager.D2 upright microscope with AxioVision 4.8 software (Carl Zeiss 
Microscopy, Thornwood, NY).  
Senescence-associated β-galactosidase staining 
Cultured cells plated into 6-well dishes one day prior to staining. Cells fixed and 
stained per manufacturer’s protocol (Senescence β-Galactosidase Staining kit, 
Cell Signaling #9860). Stained cells imaged with a Zeiss Axio Observer inverted 
scope with differential interference contrast brightfield microscopy (DIC). Ten 
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random images collected and cells counted with ImageJ 1.45s software. Staining 
performed one week post-infection or 72 hours post-transfection in triplicate. 
Fluorescence-activated cell sorting (FACS) 
Cultured cells harvested by trypsinization, counted, and 5 x 105 cells were 
pelleted by centrifugation (1000rpm, 5 minutes). Cell pellets resuspended in 500 
µl propidium iodide (PI) then incubated 20 minutes at 37°C (NuCycl protocol; 
Exalpha Biologicals, Maynard, MA). PI-stained cells were filtered and sorted on a 
FACS Calibur with 488 nm excitation (BD Biosciences).  
Quantitative real-time PCR 
Quantitative real-time PCR (qRT-PCR) performed on ABI 7500 (Applied 
Biosystems, Foster City, CA). RNA isolated with RNeasy mini kits (Qiagen, 
Valencia, CA), three independent isolations were performed for each sample. 
cDNA generated with a Super Script III kit (Invitrogen, Carlsbad, CA) per 
manufacturer’s protocol. Taqman gene expression assays (Applied Biosystems) 
for SOX10 (Hs00366918_m1), MITF (Hs00165156_m1), RB1 (Hs01078066_m1), 
p27 (Hs01597588) and E2F1 (Hs00153451_m1) were used with GAPDH 
(Hs02758991_g1) as reference gene. Alternatively, gene expression was 
measured with Sybr green I PCR mix (15.2 µl DEPC water, 2.5 µl 10X PCR 
buffer (10), 2.5 µl 10mM dNTP, 1.5 µl dimethylsulfoxide, 0.5 µl SYBR Green I 
diluted 1:1000 in DEPC water, 0.5 µl of 50uM forward and reverse primers, 25 µl 
TaKaRa LA Taq DNA polymerase) for p21 (CDKN1A). Cycling conditions were: 
94°C, 2 min; 40 cycles at 94°C, 10 sec; 60°C, 30 sec; and 70°C, 30 sec. 
Standard curve analysis performed on each gene (ABI 7500 Fast System v1.4.0 
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software) in triplicate for each biological sample. Primer sequences used in this 
analysis (5’ to 3’) were: p21 (CDKN1A) forward, ACTCTCAGGGTCGAAAACGG 
and reverse, CCTCGCGCTTCCAGGACTG (18); GAPDH forward, 
CATGACCACAGTCCATGCCATCACT and reverse, 
TGAGGTCCACCACCCTGTTGCTGTA (19).  
 
Mouse husbandry and phenotype scoring  
Mice were maintained in NIH animal facilities and all procedures approved by the 
IACUC in accordance with NIH guidelines. Grm1Tg(p18A4.B)1352Szc mice, 
hereafter Grm1Tg (20), were originally obtained on a mixed genetic background, 
then outcrossed repeatedly (>10 generations) to establish a colony on a 
predominantly C57Bl/6J background. Colonies of Sox10tm1Weg, hereafter 
named Sox10LacZ (21), Mitfmi-vga9 (hereafter Mitfvga9) (22), and Kittm1Alf mice 
(hereafter KitLacZ) (23) were also each maintained by repeated outcrossing to 
C57Bl/6J. Heterozygote carriers from each of the colonies were intercrossed with 
Grm1Tg/+ heterozygotes, and double heterozygote mice were backcrossed to 
Grm1Tg/+ heterozygotes to generate mice for analysis. 
To quantitate the severity of melanoma progression in Grm1Tg mice, detailed 
observation and photo-documentation was used to assign numerical scores of 0 
to 4 to the ears for 2 independent criteria, pigmentation and raised tumor 
severity. For scoring pigmentation, 0 indicated no visible pigmented nevi on the 
ear, and 4 indicated that 90-100% of the ear was covered in continuous 
pigmentation. For scoring degree to which nevi were raised, 0 indicated that any 
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visible pigmentation was flat with no detectable increased thickness of the skin, 
and 4 indicated a significant, raised tumor that was becoming necrotic and 
warranted euthanasia. Ventral spotting was also scored using a scale of 0 to 4 
(0=no ventral spotting; 4=severe ventral spotting extending dorsally) as 
previously described (24). 
 
Results: 
Assessment of somatic SOX10 mutations across melanoma subtypes 
Melanoma can arise in different histological locations, resulting in 
numerous subtypes with distinct protein expression patterns and genomic 
aberrations (25). Previously we identified intragenic mutations in the SOX10 
locus in a subset of samples from both primary and metastatic melanoma (10). In 
order to fully evaluate the contribution of SOX10 mutations to melanoma 
progression we expanded our analysis of SOX10 coding variations with an 
additional 153 melanoma samples representing various histological subtypes 
(Table 1). Only one novel SOX10 alteration was observed: a G to T substitution 
encoding a non-synonymous amino acid change (p.P217L) in a cell line derived 
from an acral lentiginous melanoma tumor. This altered proline is 3’ of the HMG 
binding domain, and is evolutionarily conserved from mammals to chicken. 
Although we were unable to validate that this coding alteration occurred 
somatically in this sample as normal genomic DNA from this patient was 
unavailable, query of the dbSNP database indicated the predicted P217L variant 
has not been observed previously (NCBI, dbSNP Short Genetic Variations, 
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www.ncbi.nlm.nih.gov, accessed August 22, 2012), suggesting this SOX10 DNA 
change is unique. Overall these findings suggest that maintenance of SOX10 
function is required for melanomagenesis, as melanoma cells favor the retention 
of a wild type SOX10. 
SOX10 knockdown in melanoma cells results in G1 arrest and cell 
senescence 
To assess if SOX10 is required for melanoma cells in vitro, we performed 
RNAi-mediated knockdown. Three melanoma cell lines were transduced with two 
different SOX10-specific lentiviral RNAi hairpins (shSOX10) and compared with 
lines transduced with a non-silencing control hairpin. One week post-infection, 
the shSOX10 lines showed reduced SOX10 protein levels and the cells became 
enlarged and translucent (flat) (Figure 1A-B). These cells also showed arrested 
or slowed growth (Figure 1C). Analysis of five additional melanoma lines showed 
consistent results, with six of the eight lines displaying altered cellular 
morphology and slowed growth resulting from SOX10 knockdown (data not 
shown). Three of these six lines were selected for further functional analysis: the 
0002-ARM and UACC 1022 cell lines, which contain V600E and L597S BRAF 
mutations, respectively, and the 0380-MMU cell line, which harbors an NRAS 
Q61K mutation.  
 To further characterize the arrested growth we observed in the shSOX10 
lines, we stained for β-galactosidase (SA-β-Gal), a biomarker of cellular 
senescence (Figure 1D). Significant increases in SA-β-Gal activity were seen in 
all three lines when stably transduced with shSOX10 hairpins (Figure 1E), 
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suggesting that loss of SOX10 induces senescence in melanoma cells. Another 
hallmark of cellular senescence, senescence-associated heterochromatin foci 
(SAHF), was observed upon chromatin binding protein HP1β immunostaining 
(Figure 1F and Supplemental Figure 1). Upon loss of SOX10 protein, the cells 
show more severe punctate staining of HP1β as a result of chromatin 
rearrangements brought on by senescent fate.  
 The shSOX10 cells showed no increase in APC-annexin V staining as 
compared to controls, indicating no increase in apoptosis (data not shown). 
Quantitation of the number of cells in each phase of the cell cycle by FACS 
analysis demonstrated that SOX10 knockdown cells consistently showed a 
significant increase in the population of cells in G1-phase (Figure 2A), indicative 
of G1 arrest and decreased cell cycle progression. Taken together, these data 
suggest SOX10 is required for proliferation of melanoma cells. 
SOX10 knockdown results in reduced E2F1 and RB levels   
The RB-E2F1 complex gates a fundamental checkpoint regulating 
progression through the G1-phase of the cell cycle (7). Phosphorylation releases 
RB from E2F1 during G1 and is required for the accumulation of transcriptionally 
active E2F1 (26). Thus we evaluated E2F1 and RB protein levels by Western blot 
in SOX10 knockdown cells. In all three melanoma lines, SOX10 knockdown led 
to reduced levels of E2F1 protein and total RB protein (Figure 2B). Consistent 
with these results, we found E2F1 transcript levels decreased upon SOX10 
knockdown (Figure 2C), however no change in RB mRNA levels were seen 
(Figure 2C) despite seeing less RB protein. When the degree of RB 
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phosphorylation was evaluated with an antibody specific for RB serine residues 
Ser807 and Ser811, we observed a decrease in levels of phosphorylated RB 
(Figure 2B). These data suggest that the total RB protein level decreases as a 
result of a loss of stable, phosphorylated RB and are consistent with the G1 
arrest observed. A similar destabilization of RB protein leading to G1 arrest has 
been reported in PAX8 knockdown experiments (27).  
shSOX10-induced G1 arrest is not mediated by p53 signaling 
The p53 pathway regulates the G1 cell cycle checkpoint, and p53 
activation has been shown to result in melanoma cell cycle arrest (28). Therefore 
we measured p53 protein levels in SOX10 knockdown cells. In the 0002-ARM 
cell line, p53 levels decreased with reduced SOX10 expression, however no 
change in p53 levels was observed in 0380-MMU cells (Figure 2B). For the 
UACC 1022 line, p53 was undetectable in both the control cells and shSOX10 
lines (Figure 2B). Sequencing of the TP53 locus in the UACC 1022 line identified 
a premature stop codon along with loss of heterozygosity (R195X) (data not 
shown), indicating UACC 1022 is null for p53 protein signaling. As growth arrest 
was observed in all three lines, independent of p53 status, the G1 arrest 
observed in shSOX10 cells is not solely mediated through the p53 signaling 
pathway.  
SOX10 knockdown results in decreased MITF and increased CDK inhibitors 
p21 and p27 
 As knockdown of MITF in melanoma cell lines has been shown to 
produce a similar decrease in growth rate and G1 cell cycle arrest (29), and MITF 
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is a well-established downstream transcriptional target of SOX10 (30), we 
assessed MITF expression upon shSOX10 knockdown. Reduced MITF protein 
was observed upon shSOX10 knockdown, in both 0380-MMU and 0002-ARM 
cells (Figure 2B), while MITF protein expression was undetectable by Western 
blot in UACC 1022 control cells (Figure 2B).  
 Given these altered MITF expression levels, we looked for consistent 
alterations in G1 cell cycle regulators across the three lines. CDK2, itself a 
downstream target of MITF transactivation (31), decreased in both the 0380-
MMU and UACC 1022 shSOX10 cells, and increased in the 0002-ARM shSOX10 
cells (Supplemental Figure 2). However, no consistent change in total expression 
level for CDK4, CDK6, or Cyclin D1 proteins was observed (Supplemental Figure 
2), thus CDK protein expression levels did not provide a unified mechanism to 
explain the loss of phosphorylated RB protein observed in shSOX10 cells.  
We next evaluated protein levels of p16 (CDKN2A), p21 (CDKN1A) and 
p27 (CDKN1B) following SOX10 knockdown (Figure 2B). Lowered MITF levels 
leading to G1 arrest have been correlated with an increase in p27 levels (12) and 
with decreased levels of p21, as MITF directly regulates p21 transcription 
(32)(33). We observed moderate p16 expression in 0380-MMU cells, however 
p16 levels remained unchanged following SOX10 knockdown. We consistently 
observed increases in p27 levels in all three cell lines as a result of SOX10 
knockdown (Figure 2B), similar to previous MITF knockdown studies (12). 
However, SOX10 knockdown caused an increase in p21 protein in all three cell 
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lines (Figure 2B), thus showing a distinct difference from the MITF knockdown 
results.  
 
Altered MITF and p27 gene expression occur prior to G1 arrest  
To assess changes in transcript levels prior to G1 arrest, we performed a 
transient, 72 hour siRNA knockdown of SOX10. In both 0380-MMU and UACC 
1022 cell lines, siSOX10 knockdown led to decreased SOX10 protein 
(Supplemental Figure 3), however siSOX10 knockdown did not increase SA β-
gal activity or the G1 cell population (Figure 3A-B). Consistent with the stable 
shSOX10 knockdown results, we found transient siSOX10 treatment reduced 
MITF mRNA in both cell lines, increased p27 mRNA in both cell lines, increased 
p21 mRNA in 0380-MMU cells but had no effect on p21 in UACC1022 cells, and 
had no effect on RB mRNA levels in both lines (Figure 3C-D), E2F1 message 
changes appeared to be cell type dependent (Figure 3C-D). 
 
Reduction of SOX10 expression in vivo suppresses melanomagenesis 
To assess the role of SOX10 in melanoma progression in vivo, we utilized 
a mouse model of Sox10 haploinsufficiency (Sox10LacZ/+) (21) crossed with a 
Grm1Tg mouse melanoma model (20). In human melanomas, glutamate receptor 
pathway activation is observed in tumors harboring recurrent mutations in the 
glutamate receptor genes GRM3 (34) and GRIN2A (35). Similarly, Grm1Tg mice 
harbor a transgene insertion that causes overexpression of Grm1, activates the 
glutamatergic pathway and causes numerous, pigmented nevi at weaning in 
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heterozygous and homozygous mice (Figure 4A, left two panels). Nevi in 
homozygotes (Grm1Tg/Tg) are raised by 2-3 months of age and typically 
necessitate euthanasia by 5 months of age. We crossed Grm1Tg/Tg mice with 
Sox10LacZ/+ mice, then double heterozygotes were backcrossed to Grm1Tg/Tg mice, 
thus generating Grm1Tg/+ and Grm1Tg/Tg offspring that were also haploinsufficient 
for Sox10 (Grm1Tg/+;Sox10LacZ/+ and Grm1Tg/Tg;Sox10LacZ/+, respectively) along 
with Grm1Tg/+ and Grm1Tg/Tg littermates. The extent of pigmentation and severity 
of raised tumors visible on the ears of 3-5 month old mice was quantitatively 
scored and compared among genotypes (Figure 4A-C). Sox10 haploinsufficiency 
significantly reduced the number of pigmented nevi in both Grm1Tg/+ and 
Grm1Tg/Tg mice (p<0.005), and also the severity of raised nevi in Grm1Tg/Tg mice 
(p<0.05). An extended tumor latency was also observed, with raised tumors first 
appearing in Grm1Tg/Tg;Sox10LacZ/+ mice at 5-6 months vs 2-3 months in 
Grm1Tg/Tg mice (data not shown).   
Interestingly, the Grm1Tg transgene did not suppress the 
hypopigmentation (belly spots) that is normally observed in Sox10LacZ/+ mice due 
to a developmental reduction in melanoblast number (Figure 4D-E). This 
indicates that Grm1Tg does not cause a developmental expansion of 
melanoblasts and suggests that SOX10’s role in melanoma suppression is 
independent of its effect on embryonic melanoblast number. Another white 
spotting allele with a developmental reduction in melanoblasts, KitLacZ, was not 
sufficient to suppress melanoma in Grm1Tg (Supplemental Figure 4), which is 
on March 12, 2014. © 2013 American Association for Cancer Research.cancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 1, 2013; DOI: 10.1158/0008-5472.CAN-12-4620 
 17
consistent with the separation of SOX10’s roles in developmental melanoblast 
number and melanoma formation in the Grm1Tg model.  
To understand the role of Mitf in the Sox10LacZ suppression of Grm1Tg 
mouse melanoma lesions, Grm1Tg/Tg mice were crossed to mice that harbor a 
transgene disruption that results in a functionally null allele of Mitf. In contrast to 
the Grm1Tg/+;Sox10LacZ/+ and Grm1Tg/Tg;Sox10LacZ/+ mice, heterozygosity for the 
Mitfvga9 allele did not suppress the development of hyperpigmented, raised 
lesions in the Grm1Tg/+;Mitfvga/+ and Grm1Tg/Tg;Mitfvga/+mice (Supplemental Figure 
4). Of note, Mitfvga/vga homozygotes lack melanocytes, and thus could not be 
analyzed (22)(36). In summary, Sox10 haploinsufficiency is sufficient to suppress 
the phenotype of Grm1Tg mice indicating an essential role of SOX10 in melanoma 
progression. 
 
Discussion: 
Melanoma is an aggressive tumor type that progresses rapidly and 
exhibits resistance to most current therapeutic interventions. Although targeted 
therapies to known tumor suppressor and oncogenic players in melanoma cells 
may achieve responses, patients are subject to relapse (37)(38). This study 
focuses on the role of SOX10 in melanoma, and supports mounting evidence 
suggesting SOX10 is an important lineage-specific target for patient intervention. 
Previous studies have detailed broad expression of SOX10 in melanoma tumor 
samples across various stages of disease, further suggesting a necessity for this 
protein in melanoma (39)(40)(41)(42).  
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Our sequencing analysis reveals a low frequency of intragenic 
mutations in SOX10, suggesting a preference for wild type SOX10 protein in 
melanoma formation and maintenance. Recent research has demonstrated the 
rate of “passenger” mutations, propagated by clonal expansion without any 
growth advantage, is higher in cutaneous melanoma than in solid tumors (43). 
This high passenger mutation rate was exemplified in genomic sequencing of the 
121 melanoma samples, where 518 genes were found to have mutations in  > 
10% of melanoma samples (5). Previously, we identified nine SOX10 mutations 
from two small, distinct melanoma patient cohorts. We identified 3/50 mutations 
in metastatic samples from individuals enrolled in a single clinical trial, and 7/55 
mutations from primary samples for a combined mutation rate of 8.5%. Of these, 
only the three mutations identified from samples obtained from the single 
metastatic cohort of patients were characterized by either an early truncation of 
SOX10 or an alteration leading to a C-terminal extension of SOX10 and were 
found to have reduced SOX10 functional activity (10). Given that the combined 
mutation rate (8.5%) falls within the range anticipated for melanoma, and that all 
of the confirmed functional mutations were ascertained from one patient cohort, 
we felt further analysis of the SOX10 locus was warranted. 
 In our current analysis, we increased sample numbers of mucosal and 
lentiginous melanoma subtypes and increased the diversity of clinical sources 
from which samples were collected, to reduce the potential for ascertainment 
bias. From this diverse sample cohort we found only 1/153 (<1%) of melanoma 
samples mutated for SOX10. This rate is consistent with the SOX10 mutation 
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rate identified from recent large scale sequencing of metastatic melanoma (5). 
These data show that the SOX10 mutation rate is lower than the passenger 
mutation rate, suggesting the potential preference for wild type SOX10 protein in 
melanoma formation and maintenance.  
Consistent with this finding, we hypothesize that SOX10 regulates 
melanoma cell proliferation and cell cycle regulation via multiple, convergent 
pathways regulating RB and E2F1 levels. Reduction in SOX10 levels results in 
increased expression of p21 and p27, inhibitors of CDKs which regulate multiple, 
sequential phosphorylation events on RB necessary for cell cycle progression. 
The E2F1-RB complex provides a cellular checkpoint for cell cycle progression 
out of G1. RB in its hypophosphorylated state prevents cells from entering S-
phase and arrests them at G1. E2F1 level regulation is a key mediator of 
progression through G1, as E2F1 functions to activate downstream targets 
required for entry into S phase. Since we observed a change in E2F1 RNA levels 
combined with a senescent cellular phenotype when SOX10 expression was 
decreased in melanoma cell lines, we postulate that SOX10, or a downstream 
target, is required for proper regulation of E2F1 and subsequent control of cell 
proliferation through RB-E2F1 signaling. This is in contrast to what is observed 
for RB, where RB protein is reduced but transcript expression is unchanged 
following SOX10 reduction. We cannot exclude the possibility that SOX10 could 
indirectly stabilize the RB protein to prevent proteasomal degradation. In fact, the 
reduction in total RB protein may be a result of SOX10-mediated reduction in 
E2F1 levels, as reduced levels of active RB have been shown to be a direct 
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consequence of decreased E2F1 expression (44) as well as increased p27 and 
p21 levels, ultimately resulting in more unstable hypophosphorylated RB protein 
(45).  
Studies involving human melanoma cell lines can be limited due to the 
heterogeneity and phenotypic variations resulting from context-dependent effects 
on the genome. The melanoma cell lines described in this study mirror that 
heterogeneity, showing differences in p53 status, p16ARF and MITF expression 
levels, and mutation status of the major oncogenes NRAS and BRAF. Despite 
these notable variations, a dysregulated cell cycle with altered RB and E2F1 
levels was consistently observed upon loss of SOX10 protein. Initially we 
hypothesized that MITF, which itself is a direct transcriptional target of SOX10, 
was appropriately poised to be the responsible transcription factor. Although 
RNAi-mediated reduction of MITF also leads to a senescent morphology and G1 
cell arrest (13), this occurred in conjunction with a decrease in p21 expression, 
which was not observed in our study of SOX10 knockdown. These results may 
have potential implications clinically given the heterogeneity that exists within 
melanoma tumors. Importantly, the consistent observation that SOX10 is 
required for proliferation of melanoma cells suggests that SOX10 or its 
downstream targets are involved in the regulation of cell cycle. 
The frequent acquired resistance to current BRAF inhibitors observed in 
recent clinical trials is mediated by re-acquisition of increased MAPK signaling 
(46). These results highlight the need for a more comprehensive understanding 
of all aspects of cell cycle dysregulation that occurs as a result of increased 
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MAPK signaling in tumors, and the need to evaluate additional mechanisms that 
have the capacity to reduce cell proliferation and tumor formation. We find that 
SOX10 has a pivotal role in melanoma cell proliferation not only in cell culture, 
but also in vivo, as Sox10 haploinsufficiency prevents the formation of 
hyperpigmented lesions observed in the Grm1Tg mouse melanoma model. A 
recent study by Shakhova et al. reported a similar reduction in tumor formation 
when SOX10 levels were reduced in the context of the NrasQ61K-driven mouse 
melanoma model (47). Together these studies show that distinct melanoma 
drivers require SOX10 for tumor formation and maintenance. Both NRAS and 
GRM1 activate the MAPK and PI3K/AKT signaling pathways, which are 
fundamental to melanomagenesis. Given that both the NrasQ61K and the Grm1Tg 
mouse melanoma models are rescued with Sox10 haploinsufficiency, SOX10 
may occupy an important position of regulation of oncogenic cell cycle 
progression downstream of one or both of these signaling pathways. Interestingly, 
the Grm1Tg mouse melanoma model is not rescued with the Mitfvga9 mouse, 
suggesting that either this cross did not result in a sufficient loss in Mitf 
expression, as Mitfvga/+ mice have been demonstrated to exhibit a 50% reduction 
in melanocyte MITF levels (22), or that SOX10 is involved in key melanoma 
pathways independent of its regulation of Mitf levels. When these data are 
combined with the extensive occurrence of SOX10-positive cells in both primary 
and metastatic tumors (41), the frequent tumor retention of wild-type SOX10 
protein, and the effect of reduced SOX10 levels on RB and E2F1 levels leading 
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to decreased cell cycle progression and melanoma cell proliferation, SOX10 is 
revealed as an notable molecule for further assessment as a therapeutic target. 
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Figure Legends 
 
Figure 1. SOX10 depletion triggers arrested growth and melanoma cell 
senescence 
A. Western blot analysis of SOX10 expression in 0380-MMU cell lysates stably 
transduced with a non-silencing control hairpin (NS) or SOX10-specific lentiviral 
RNAi hairpins (sh1 and sh2). B. Phase-contrast images of 0380-MMU stable cell 
lines, 1 week post-infection with NS or SOX10sh1. C. Proliferation assays for 
0380-MMU, UACC 1022, and 0002-ARM cell lines transduced with NS, sh1, or 
sh2. Cells were counted in triplicate 1 to 14 days after plating, and proliferation 
assays were performed at least twice with subsequent infections. D. 
Representative images of 0380-MMU cells stained for SA-β-Gal activity one 
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week post-infection with NS, SOX10sh1 and SOX10sh2. E. Significant increases 
in the percentage of SA-β-Gal positive cells were seen in SOX10sh lines relative 
to NS lines, as determined by t-test (for 0380-MMU, sh1 p<7.32x10-5, sh2 
p<7.95x10-3; for UACC 1022, sh1 p<5.49x10-11, sh2 p<2.17x10-8; for 0002-ARM, 
sh1 p<2.90x10-5, sh2 p<8.80x10-5). F. Stably transduced UACC 1022 cell lines 
stained with anti-SOX10, anti-HP1β antibodies and DAPI nuclei counterstain. 
HP1β staining indicated the presence of senescence-associated heterochromatin 
foci in SOX10sh1 cells. Scale bar = 10 μm. 
 
Figure 2. Cell cycle arrest and expression changes in cell cycle regulators are 
observed upon stable loss of SOX10    
A. Significant increases in G1 cell populations were observed in 0380-MMU, 
UACC 1022, and 0002-ARM lines stably transduced with SOX10-specific 
hairpins (sh1 and sh2) relative to lines stably transduced with a non-silencing 
control hairpin (NS) (t-test p values were: 0380-MMU, sh1 = p<0.007, sh2 = 
p<0.026; UACC 1022 sh1 = p<0.026, sh2 = 0.17; 0002-ARM sh1 = p<0.023, sh2 
= p<0.03). FACS analysis on each line was repeated twice with subsequent 
infections. B. Western blot analysis of the effects of NS, sh1 and sh2 stable 
transduction in each line on important cell cycle regulatory proteins. C. 
Quantitative RT-PCR of RNA isolated from 0380-MMU NS and sh1 stable lines 
showed significant changes in SOX10 (p<0.006), MITF (p<0.0005), E2F1 
(p<0.005) and p21 (p<0.016) expression as determined by t-test. Data are fold 
change normalized to control, and the average of three replicate assays. 
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Figure 3. Altered MITF, p21 and E2F1 expression precedes G1 cell cycle arrest 
A. Quantification of the percentages of SA-β-Gal-positive cells in 0380-MMU and 
UACC 1022 cells transiently transfected with non-silencing (NS) or SOX10-
specific (si1 and si2) siRNA showed no significant differences. B. No significant 
differences were seen in G1 cell populations in 0380-MMU and UACC 1022 
melanoma cell lines transiently transfected with NS, si1, or si2. FACS analysis on 
independent cell lines was repeated twice with subsequent transfections. C-D. 
Quantitative RT-PCR analysis of (C) UACC 1022 and (D) 0380-MMU cell lines 
transiently transfected with NS or siSOX10. Data are fold change normalized to 
NS control. siSOX10-transfected UACC 1022 cells showed significant changes in 
expression of SOX10 (p<0.05), MITF (p<0.0004), and E2F1 (p<0.001). siSOX10-
transfected 0380-MMU cells showed significant changes in the expression of 
SOX10 (p<0.01), MITF (p<0.007), E2F1 (p<0.001); p21 and p27 showed 
increased expression that did not achieve statistical significance. Data analyzed 
by Student’s t-test. 
 
Figure 4. SOX10 expression is required for melanoma progression in vivo 
A. Grm1Tg/+;Sox10+/+ mice show moderate ear hyperpigmentation (top left panel). 
This phenotype is exaggerated in Grm1Tg/Tg;Sox10+/+ mice, where the pigmented 
lesions are raised (bottom left panel). Haploinsufficiency for SOX10 (Sox10LacZ/+) 
in conjunction with one or two Grm1Tg alleles reduces pigmented ear lesions 
(right two panels).  B,C. Grm1Tg phenotypic severity either alone or in the context 
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of Sox10 haploinsufficiency was quantitatively measured by scoring each 
individual animal on a scale of 1-4 for (B) the extent of pigmentation and (C) 
burden of raised tumors. Sox10 haploinsufficiency significantly reduced 
pigmented nevi (p<0.005) in both Grm1Tg/+ and Grm1Tg/Tg mice, and also the 
extent to which they were raised (p<0.05) in Grm1Tg/Tg mice (Mann-Whitney test 
with Bonferonni correction). D. No ventral spotting was observed in Grm1Tg/+ or 
Grm1Tg/Tg mice that were also Sox10+/+ (left two panels), and the presence of one 
or two Grm1Tg/+ alleles did not affect ventral spotting caused by the Sox10LacZ 
allele. (right two panels; mice shown received a spotting severity score of two).  E. 
Quantitative scoring of belly spots in Sox10LacZ; Grm1+/+, Sox10LacZ; Grm1Tg/+, 
and Sox10LacZ; Grm1Tg/Tg mice showed no significant differences (p=0.3342; 
Kruskal-Wallis nonparametric one-way ANOVA). 
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